Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 1.00 |
| ▸ | NPC1 | O15118 | 7/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 6/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | GAA | P10253 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 2/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 2/20 | 1.00 |
| ▸ | RELA | Q04206 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | CCR6 | P51684 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661048 | 1.00 | RAB9A (1.00) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL26677841 | 0.98 | RAB9A (0.96) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Bromide SCHEMBL26677852 | 0.98 | RAB9A (0.96) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL26677838 | 0.98 | RAB9A (0.96) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Oxalic Acid SCHEMBL26677840 | 0.92 | NPC1 (0.84) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Phosphoric Acid SCHEMBL26677843 | 0.92 | NPC1 (0.84) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Sulfuric Acid SCHEMBL26677844 | 0.92 | NPC1 (0.84) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Acetic Acid SCHEMBL26677848 | 0.90 | NPC1 (0.81) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| SCHEMBL26677839 | 0.90 | NPC1 (0.81) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 | |
| Fumaric Acid SCHEMBL26677847 | 0.87 | NPC1 (0.77) | RAB9ANPC1NPSR1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576088-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | NORTHWESTERN UNIVERSITY (US) | 2026-03-17 | — | — | US | claimed |
| US-20240066035-A1 | Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B | NORTHWESTERN UNIVERSITY | 2024-02-29 | — | — | US | claimed |
| CN-117137914-A | Use of N- (pyridin-2-yl) pyridine-2-thioamides or salts thereof in the preparation of anti-hypoxic drugs | 中国人民解放军军事科学院军事医学研究院 | 2023-12-01 | — | — | CN | claimed |
| WO-2023226614-A1 | USE OF N-(PYRIDIN-2-YL)PYRIDINE-2-THIOAMIDE OR SALT THEREOF IN PREPARATION OF ANTI-HYPOXIC MEDICAMENT | 中国人民解放军军事科学院军事医学研究院 | 2023-11-30 | — | — | WO | claimed |
| US-11793816-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | NORTHWESTERN UNIVERSITY (US) | 2023-10-24 | — | — | US | claimed |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY | 2022-10-13 | — | — | US | claimed |
| US-20210069202-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH INHIBITION OF ATG4B | NORTHWESTERN UNIVERSITY | 2021-03-11 | — | — | US | claimed |
| WO-2020223609-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | NEW YORK UNIVERSITY (US) | 2020-11-05 | — | — | WO | claimed |
| EP-3523274-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. (US) | 2019-08-14 | — | — | EP | claimed |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2019-05-09 | — | — | US | claimed |
| US-20190091187-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS INCLUDING GLIOMAS | Orbus Therapeutics, Inc. (US) | 2019-03-28 | — | — | US | claimed |
| EP-3432872-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2018067401-A1 | FORMULATIONS FOR ADMINISTRATION OF EFLORNITHINE | Orbus Therapeutics, Inc. (US) | 2018-04-12 | — | — | WO | claimed |
| US-20170273926-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. | 2017-09-28 | — | — | US | claimed |
| WO-2017165187-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | Orbus Therapeutics, Inc. (US) | 2017-09-28 | — | — | WO | claimed |
| US-8545841-B2 | Methods and compositions for the treatment of cancers and pathogenic infections | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-10-01 | — | — | US | claimed |
| US-20100285012-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INC. (US) | 2010-11-11 | — | — | US | claimed |
| WO-2009089147-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-07-16 | — | — | WO | claimed |
| US-12576088-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | NORTHWESTERN UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2009089147-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCERS AND PATHOGENIC INFECTIONS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091187-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS INCLUDING GLIOMAS | AHCY, SRM, SHMT1 | RAB9A 1592/4885NPC1 1213/4885NPSR1 4721/4885 |
| US-20240066035-A1 | Methods for Enhancing Cytotoxic Cancer Therapy Through Inhibition of ATG4B | ATG4B, ATG4A, ATG7 | RAB9A 494/4885NPC1 543/4885NPSR1 4664/4885 |
| US-20210069202-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH INHIBITION OF ATG4B | ATG4B, ATG4A, ATG7 | RAB9A 494/4885NPC1 543/4885NPSR1 4664/4885 |
| US-20220323376-A1 | METHODS AND COMPOSITIONS FOR SENSITIZING CANCER CELLS TO DRUG-INDUCED APOPTOSIS | MCL1, BAX, CASP3 | RAB9A 3420/4885NPC1 1422/4885NPSR1 4487/4885 |
| US-11793816-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | ATG4B, ATG4A, ATG7 | RAB9A 494/4885NPC1 543/4885NPSR1 4664/4885 |
| US-20190133985-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, MAT2A | RAB9A 1629/4885NPC1 1117/4885NPSR1 4657/4885 |
| US-12576088-B2 | Methods for enhancing cytotoxic cancer therapy through inhibition of ATG4B | ATG4B, ATG4A, ATG7 | RAB9A 436/4885NPC1 752/4885NPSR1 4741/4885 |
| US-20170273926-A1 | COMPOSITIONS AND METHODS FOR USE OF EFLORNITHINE AND DERIVATIVES AND ANALOGS THEREOF TO TREAT CANCERS, INCLUDING GLIOMAS | AHCY, SRM, SHMT1 | RAB9A 1589/4885NPC1 1166/4885NPSR1 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.